Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Trogarzo 30 sec i.v. push over two weeks

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Oct 03, 2022 5:30pm

108 Views

Post# 35002641

RE:RE:Trogarzo 30 sec i.v. push over two weeks

I disagree, for patients that does not fear needles I would take an injection every two weeks over pills.

SPCEO1 wrote: It at least gives them an excuse to get in front of more key clinic people to explain the benefits of Trogarzo IV Pushand bring up Egrifta as well. When Trogarzo's IV version was first approved, Egrifta sales really benefited from the greater access the reps had to the doctors for a while. I would not expect a giant sales jump from Trogarzo as Fostemsavir is a pill, which is still better than a 30 second needle.

Joemare wrote: At least, this news will make the reps happy and further motivated as they got rid of a strong push-back. The ball is in their court.